182 related articles for article (PubMed ID: 27155464)
21. Design, Synthesis, and Biological Evaluation of Substituted Pyrimidines as Potential Phosphatidylinositol 3-Kinase (PI3K) Inhibitors.
Zhang JQ; Luo YJ; Xiong YS; Yu Y; Tu ZC; Long ZJ; Lai XJ; Chen HX; Luo Y; Weng J; Lu G
J Med Chem; 2016 Aug; 59(15):7268-74. PubMed ID: 27427973
[TBL] [Abstract][Full Text] [Related]
22. Design, synthesis and bioevaluation of N-trisubstituted pyrimidine derivatives as potent aurora A kinase inhibitors.
Luo Y; Deng YQ; Wang J; Long ZJ; Tu ZC; Peng W; Zhang JQ; Liu Q; Lu G
Eur J Med Chem; 2014 May; 78():65-71. PubMed ID: 24681066
[TBL] [Abstract][Full Text] [Related]
23. 4-Substituted-1-phenyl-1H-pyrazolo[3,4-d]pyrimidine derivatives: design, synthesis, antitumor and EGFR tyrosine kinase inhibitory activity.
Abbas SE; Aly EI; Awadallah FM; Mahmoud WR
Chem Biol Drug Des; 2015 May; 85(5):608-22. PubMed ID: 25318985
[TBL] [Abstract][Full Text] [Related]
24. Synthesis and biological evaluation of new pyrimidine-4-yl-ethanol derivatives as ROS1 kinase inhibitors.
Abdelazem AZ; Lee SH
J Enzyme Inhib Med Chem; 2015 Apr; 30(2):290-8. PubMed ID: 24939104
[TBL] [Abstract][Full Text] [Related]
25. Design, synthesis and anticancer studies of novel aminobenzazolyl pyrimidines as tyrosine kinase inhibitors.
Chikhale R; Thorat S; Choudhary RK; Gadewal N; Khedekar P
Bioorg Chem; 2018 Apr; 77():84-100. PubMed ID: 29342447
[TBL] [Abstract][Full Text] [Related]
26. Design, Synthesis and Biological Evaluation of Some 5-Arylthieno[2,3-d]pyrimidines as Potential Anti-cancer Agents.
El-Ansary AK; Kamal AM; Al-Ghorafi MA
Chem Pharm Bull (Tokyo); 2016; 64(8):1172-80. PubMed ID: 27477657
[TBL] [Abstract][Full Text] [Related]
27. Novel pyrazolo[3,4-d]pyrimidines as dual Src-Abl inhibitors active against mutant form of Abl and the leukemia K-562 cell line.
El-Moghazy SM; George RF; Osman EEA; Elbatrawy AA; Kissova M; Colombo A; Crespan E; Maga G
Eur J Med Chem; 2016 Nov; 123():1-13. PubMed ID: 27474918
[TBL] [Abstract][Full Text] [Related]
28. Discovery of novel Bcr-Abl inhibitors targeting myristoyl pocket and ATP site.
Dong J; Lu W; Pan X; Su P; Shi Y; Wang J; Zhang J
Bioorg Med Chem; 2014 Dec; 22(24):6876-84. PubMed ID: 25464886
[TBL] [Abstract][Full Text] [Related]
29. Single step synthesis of new fused pyrimidine derivatives and their evaluation as potent Aurora-A kinase inhibitors.
Shaaban MR; Saleh TS; Mayhoub AS; Farag AM
Eur J Med Chem; 2011 Sep; 46(9):3690-5. PubMed ID: 21664013
[TBL] [Abstract][Full Text] [Related]
30. Pyrrolo[2,3-d]pyrimidine derivatives as inhibitors of RET: Design, synthesis and biological evaluation.
Lakkaniga NR; Gunaganti N; Zhang L; Belachew B; Frett B; Leung YK; Li HY
Eur J Med Chem; 2020 Nov; 206():112691. PubMed ID: 32823007
[TBL] [Abstract][Full Text] [Related]
31. Design, synthesis, and biological evaluation of novel pyrimidine derivatives as CDK2 inhibitors.
Ibrahim DA; El-Metwally AM
Eur J Med Chem; 2010 Mar; 45(3):1158-66. PubMed ID: 20045222
[TBL] [Abstract][Full Text] [Related]
32. Apoptosis in chronic myeloid leukemia cells transiently treated with imatinib or dasatinib is caused by residual BCR-ABL kinase inhibition.
Simara P; Stejskal S; Koutna I; Potesil D; Tesarova L; Potesilova M; Zdrahal Z; Mayer J
Am J Hematol; 2013 May; 88(5):385-93. PubMed ID: 23420553
[TBL] [Abstract][Full Text] [Related]
33. Synthesis and kinase inhibitory activity of new sulfonamide derivatives of pyrazolo[4,3-e][1,2,4]triazines.
Mojzych M; Šubertová V; Bielawska A; Bielawski K; Bazgier V; Berka K; Gucký T; Fornal E; Kryštof V
Eur J Med Chem; 2014 May; 78():217-24. PubMed ID: 24681986
[TBL] [Abstract][Full Text] [Related]
34. Eco-friendly Synthesis of Pyrido[2,3-d]pyrimidine Analogs and Their Anticancer and Tyrosine Kinase Inhibition Activities.
El-Naggar AM; Khalil AK; Zeidan HM; El-Sayed WM
Anticancer Agents Med Chem; 2017; 17(12):1644-1651. PubMed ID: 28403776
[TBL] [Abstract][Full Text] [Related]
35. Novel heterocyclic-fused pyrimidine derivatives: synthesis, molecular modeling and pharmacological screening.
Arafa RK; Nour MS; El-Sayed NA
Eur J Med Chem; 2013 Nov; 69():498-507. PubMed ID: 24090920
[TBL] [Abstract][Full Text] [Related]
36. Design, synthesis, and biological activity of 4-(imidazo[1,2-b]pyridazin-3-yl)-1H-pyrazol-1-yl-phenylbenzamide derivatives as BCR-ABL kinase inhibitors.
Hu L; Cao T; Lv Y; Ding Y; Yang L; Zhang Q; Guo M
Bioorg Med Chem Lett; 2016 Dec; 26(23):5830-5835. PubMed ID: 28029512
[TBL] [Abstract][Full Text] [Related]
37. Design, synthesis, and biological evaluation of pyrazolo[3,4-d]pyrimidines active in vivo on the Bcr-Abl T315I mutant.
Radi M; Tintori C; Musumeci F; Brullo C; Zamperini C; Dreassi E; Fallacara AL; Vignaroli G; Crespan E; Zanoli S; Laurenzana I; Filippi I; Maga G; Schenone S; Angelucci A; Botta M
J Med Chem; 2013 Jul; 56(13):5382-94. PubMed ID: 23746084
[TBL] [Abstract][Full Text] [Related]
38. Transient potent BCR-ABL inhibition is sufficient to commit chronic myeloid leukemia cells irreversibly to apoptosis.
Shah NP; Kasap C; Weier C; Balbas M; Nicoll JM; Bleickardt E; Nicaise C; Sawyers CL
Cancer Cell; 2008 Dec; 14(6):485-93. PubMed ID: 19061839
[TBL] [Abstract][Full Text] [Related]
39. Design, synthesis and antitumor activity of novel thiophene-pyrimidine derivatives as EGFR inhibitors overcoming T790M and L858R/T790M mutations.
Xiao Z; Zhou Z; Chu C; Zhang Q; Zhou L; Yang Z; Li X; Yu L; Zheng P; Xu S; Zhu W
Eur J Med Chem; 2020 Oct; 203():112511. PubMed ID: 32679450
[TBL] [Abstract][Full Text] [Related]
40. Synthesis and anticancer activity of novel 2-pyridyl hexahyrocyclooctathieno[2,3-d]pyrimidine derivatives.
Kassab AE; Gedawy EM
Eur J Med Chem; 2013 May; 63():224-30. PubMed ID: 23501108
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
